research
Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain tumors has not been elucidated yet, and it is difficult to treat patients because the tumors do not respond to existing antiepileptic drugs and debilitate children’s development.
A research team led by Professor Jeong Ho Lee of the Graduate School of Medical Science and Engineering has recently identified a neuronal BRAF somatic mutation that causes intrinsic epileptogenicity in pediatric brain tumors. Their research results were published online in Nature Medicine on September 17.
The research team studied patients’ tissue diagnosed with ganglioglioma (GG), one of the main causes of tumor-associated intractable epilepsy, and found that the BRAF V600E somatic mutation is involved in the development of neural stem cells by using deep DNA sequencing. This mutation was carried out in an animal model to reproduce the pathology of GG and to observe seizures to establish an animal model for the treatment of epileptic seizures caused by pediatric brain tumors.
Using immunohistochemical and transcriptome analysis, they realized that the BRAF V600E mutation that arose in early progenitor cells during embryonic brain formation led to the acquisition of intrinsic epileptogenic properties in neuronal lineage cells, whereas tumorigenic properties were attributed to a high proliferation of glial lineage cells exhibiting the mutation. Notably, researchers found that seizures in mice were significantly alleviated by intraventricular infusion of the BRAF V600E inhibitor, Vemurafenib, a clinical anticancer drug.
The authors said, “Our study offers the first direct evidence that the BRAF somatic mutation arising from neural stem cells plays a key role in epileptogenesis in the brain tumor. This study also showed a new therapeutic target for tumor-associated epileptic disorders.”
In collaboration with the KAIST startup company, SoVarGen, the research team is currently developing innovative therapeutics for epileptic seizures derived from pediatric brain tumors. This study was supported by the Suh Kyungbae Foundation (SUHF) and the Citizens United for Research in Epilepsy.
(Figure: Preoperative and postoperative brain MRI (left panel), tumor H&E (right upper panel) and GFAP immunohistochemical (right lower panel) staining images from a patient with ganglioglioma (GG231) carrying the BRAFV600E mutation. The white arrow and the black arrowhead indicate the brain tumor and a dysplastic neuron, respectively.)
-
research Simultaneous Analysis of 21 Chemical Reactions... AI to Transform New Drug Development
< Photo 1. (From left) Professor Hyunwoo Kim and students Donghun Kim and Gyeongseon Choi in the Integrated M.S./Ph.D. program of the Department of Chemistry > Thalidomide, a drug once used to alleviate morning sickness in pregnant women, exhibits distinct properties due to its optical isomers* in the body: one isomer has a sedative effect, while the other causes severe side effects like birth defects. As this example illustrates, precise organic synthesis techniques, which selectivel
2025-06-16 -
event KAIST Holds a Ceremony to Declare their Renewed Commitment for Ethical Management
KAIST held a ceremony to declare their renewed "Commitment for Ethical Management" to raise awareness and solidify the commitment its members to faithfully fulfill ethical responsibilities and duties. Last March, the university established the 'Special Committee for Ethical Management,' chaired by the Provost, and under the leadership of this committee, a new 'Code of Ethics' and 'Code of Conduct' were prepared, containing ethical standards that members must adhere to across all areas of educ
2025-06-16 -
research “One Experiment Is All It Takes”: KAIST Team Revolutionizes Drug Interaction Testing, Replacing 60,000 Studies
A groundbreaking new method developed by researchers at KAIST and Chungnam National University could drastically streamline drug interaction testing — replacing dozens of traditional experiments with just one. The research, led by Professor Jae Kyoung Kim of KAIST Department of Mathematical Sciences & IBS Biomedical Mathematics Group and Professor Sang Kyum Kim of Chungnam National University's College of Pharmacy, introduces a novel analysis technique called 50-BOA, published in Natu
2025-06-16 -
research High-Resolution Spectrometer that Fits into Smartphones Developed by KAIST Researchers
- Professor Mooseok Jang's research team at the Department of Bio and Brain Engineering develops an ultra-compact, high-resolution spectrometer using 'double-layer disordered metasurfaces' that generate unique random patterns depending on light's color. - Unlike conventional dispersion-based spectrometers that were difficult to apply to portable devices, this new concept spectrometer technology achieves 1nm-level high resolution in a device smaller than 1cm, comparable in size to a fingernail
2025-06-13 -
research KAIST Predicts Diseases by Early Detection of Aging Signals in Liver Tissue
- KAIST-KRIBB Develops ‘FiNi-seq’ Technology to Capture Characteristics of Fibrotic Microenvironments Accumulated in Liver Tissue and Dynamic Changes of Early Aging Cells - Elucidation of the Spatial Ecosystem of Aged Liver Tissue, where Reprogramming of Senescent Cells and Immune Exhaustion Progresses, at the Single-Cell Genome and Epigenome Levels < (From left) Professor Jong-Eun Park of KAIST Graduate School of Medical Science and Engineering (GSMSE), Dr. Chuna Kim of K
2025-06-12